- More than 8% of all prescriptions in September 2026 were for GLP-1 RAs, increasing slightly (+7.0%) since June 2026.
- Tirzepatide remained the leading anti-obesity medication (AOM) and anti-diabetic medication (ADM) by prescription volume and showed the largest increase in total prescribing, particularly when prescribed for obesity, from June to September 2026. Semaglutide prescribing remained relatively stable.
- Following FDA approval in April 2026, orforglipron (Foundayo pill) prescribing doubled from June 2026 to September 2026, although overall prescribing remained low at 0.12% of all prescriptions in September 2026.
- After rising by more than 50% from December 2025 to March 2026, first-time AOM semaglutide (inclusive of Wegovy and the Wegovy pill) prescribing declined by 12.5% from June to September 2026.
Limited recent data exist on prescribing patterns and patient characteristics for GLP-1 RA medications, whether used as anti-diabetic medication (ADM) for patients with type 2 diabetes (T2D) and/or used as an anti-obesity medication (AOM) for patients with overweight or obesity. Interest in these medications has recently accelerated, although access to and use of GLP-1 RA medications may be impacted by high cost, limited insurance coverage for patients without T2D, and medication shortages.
To offer insight into the latest trends about these medications, Truveta Research has created the GLP-1 RA monitoring report, which will be updated periodically with fresh, timely data. Truveta Data provides the most representative, complete, and timely patient journey data, including full patient medical records, notes, and images, for more than 140 million patients across the US. Truveta Data is also linked with closed claims, mortality, and social drivers of health. Because Truveta Data is updated daily, we can show the latest trends in these medications.
This blog provides a snapshot of the key findings in the most recent report; including prescribing and dispensing medication (indicates whether the patient picked up the medication) trends. For the full analysis—inclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citations—you can view the complete report directly within Truveta.
Key findings: Prescribing trends
Using a subset of Truveta Data, Truveta Research identified people who were prescribed a GLP-1 RA between January 01, 2019 and September 30, 2026. The report describes prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use (e.g., ADM, AOM, or unknown).
Overall prescribing trends
The study found that 4,458,532 patients were prescribed a GLP-1 RA between January 2019 and September 2026, with 23,616,330 total prescriptions during this period.
Overall prescribing rates (GLP-1 RA prescriptions as a proportion of all prescriptions) increased 7.0% from June to September 2026.
As of September 2026, more than 8 out of every 100 prescriptions were for GLP-1 RAs.
Month-over-month AOM prescribing increased most from June to July 2026 and remained relatively steady through September 2026 (+12.2%). The largest increase came from AOM tirzepatide prescriptions (+16.9%), which accounted for most of the overall increase. The June-to-July increase in AOM prescribing coincided with the July 1 implementation of the Medicare GLP-1 Bridge program and may reflect expanded access to GLP-1 RAs for weight management through the program.
Tirzepatide remains the leading AOM and ADM by prescription volume and continued to increase in total prescribing from June to September 2026 (+11.0%).
Trends in first-time prescribing
First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) increased from June to July 2026, then declined in August and September. By September 2026, first-time prescribing rates were similar to June 2026 (-1.8%).
First-time AOM prescribing increased from June to July 2026, then declined and remained relatively steady through September. Overall, first-time AOM prescribing in September was similar to June (+3.7%). First-time AOM tirzepatide prescribing increased 10.1%, while AOM orforglipron prescribing nearly doubled (+83.0%), although overall first-time prescribing of AOM orforglipron remained low.
Similar to overall prescribing, the June-to-July increase in first-time AOM prescribing coincided with the July 1 implementation of the Medicare GLP-1 Bridge program and may reflect expanded access to GLP-1 RAs for weight management through the program.
Discussion
The latest report highlights the continued popularity of GLP-1 medications, now including the newly approved oral GLP-1 RA orforglipron (sold as Foundayo).
With the popularity of GLP-1 RA medications and challenges in access and insurance coverage, we will continue to monitor prescribing over time.
The GLP-1 RA monitoring report describes more detailed information about the overall population of patients being prescribed these medications (including demographics and comorbidities), and the proportion and characteristics of patients who filled a GLP-1 RA prescription over time using dispenses. Methodologies, limitations, and citations are also available in the full report accessible directly in Truveta.
These are preliminary research findings and not peer reviewed. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed October 23, 2026. Data presented in this analysis represent raw counts and/or rates, and post-stratification methods have not been conducted.
